134 related articles for article (PubMed ID: 38634839)
21. Comparative review of imipenem/cilastatin versus meropenem.
Salmon-Rousseau A; Martins C; Blot M; Buisson M; Mahy S; Chavanet P; Piroth L
Med Mal Infect; 2020 Jun; 50(4):316-322. PubMed ID: 32035719
[TBL] [Abstract][Full Text] [Related]
22. Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin.
Bauer SL; Wall GC; Skoglund KJ; Peters LK
J Allergy Clin Immunol; 2004 Jan; 113(1):173-5. PubMed ID: 14713926
[No Abstract] [Full Text] [Related]
23. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
[TBL] [Abstract][Full Text] [Related]
24. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
[TBL] [Abstract][Full Text] [Related]
25. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
26. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
[TBL] [Abstract][Full Text] [Related]
27. Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins.
Romano A; Gaeta F; Valluzzi RL; Alonzi C; Maggioletti M; Zaffiro A; Caruso C; Quaratino D
Allergy; 2013 Dec; 68(12):1618-21. PubMed ID: 24180646
[TBL] [Abstract][Full Text] [Related]
28. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
29. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
Cox CE; Holloway WJ; Geckler RW
Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
[TBL] [Abstract][Full Text] [Related]
30. Does nephrotoxicity develop less frequently when vancomycin is combined with imipenem-cilastatin than with meropenem? A comparative study.
Hakeam HA; AlAnazi L; Mansour R; AlFudail S; AlMarzouq F
Infect Dis (Lond); 2019 Aug; 51(8):578-584. PubMed ID: 31122098
[No Abstract] [Full Text] [Related]
31. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
[TBL] [Abstract][Full Text] [Related]
32. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
33. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL; Smith JW; Geckler RW; Wilson SE
South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
[TBL] [Abstract][Full Text] [Related]
34. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins.
Gaeta F; Valluzzi RL; Alonzi C; Maggioletti M; Caruso C; Romano A
J Allergy Clin Immunol; 2015 Apr; 135(4):972-976. PubMed ID: 25457154
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
Edwards SJ; Campbell HE; Plumb JM
Eur J Health Econ; 2006 Mar; 7(1):72-8. PubMed ID: 16429296
[TBL] [Abstract][Full Text] [Related]
36. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
[TBL] [Abstract][Full Text] [Related]
38. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
Day IP; Goudie J; Nishiki K; Williams PD
Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
[TBL] [Abstract][Full Text] [Related]
39. Carbapenems in serious infections: a risk-benefit assessment.
Norrby SR
Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
